Summary LY231514 (N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]-benzoyl]-L-glutamic acid) is a new folatebased antimetabolite currently in broad phase II clinical evaluation. Previous in vitro studies (C. Shih et al, Cancer Res 57: 1116-1123 have suggested that LY231514 could be a multitargeted antifolate (MTA) capable of inhibiting thymidylate synthase (TS), dihydrofolate reductase (DHFR) and glycinamide ribonucleotide formyltransferase (GARFT). The present study compared LY231514 with methotrexate, raltitrexed and a glycinamide ribonucleotide formyltransferase inhibitor, LY309887, at 300, 100, 30 and 100 nM, respectively, for their effects on intracellular folate and at 100, 66, 20 and 30 nM respectively, for their effects on nucleoside triphosphate pools in CCRF-CEM cells.
Because of their crucial role in the biosynthesis of nucleotide precursors, folate-requiring enzymes have been attractive targets of cancer drug discovery for many years. In the past 20 years, many folate analogues have been synthesized that have been found to be active against TS and DHFR in the thymidylate cycle and against GARFT, an enzyme in the de novo biosynthesis of purines ( Figure 1 ). A number of compounds are currently being investigated clinically; some examples of these include the TS inhibitors, raltitrexed (ZD 1694), AG337 and BW1843U89, the DHFR inhibitor edatrexate and the GARFT inhibitors lometrexol and LY309887 (Jackman and Calvert, 1995; Hanauske, 1996; Mendelsohn et al, 1996) .
LY231514 is a structurally novel folate analogue that possesses a 6-5-fused pyrrolo [2,3-d] pyrimidine nucleus instead of the more common 6-6-fused pteridine or quinazoline ring structures ( Figure  2) . In preclinical models, LY231514 has shown activity against several tumour types. In vitro, it is highly toxic against CCRF-CEM human leukaemia cells in cell culture, with a 50% inhibitory concentration (for 72 h continuous drug exposure and is designated simply as IC50) of 25 nm (Taylor et al, 1992; Shih et al, 1997) .
Interestingly, the cytotoxicity of LY231514 was found to be only partly alleviated by the addition of thymidine to the medium. While
Correspondence to: VJ Chen hypoxanthine alone afforded no reversal, the combination of thymidine and hypoxanthine completely protected cells against the toxicity of LY231514 (Taylor et al, 1992) . The mechanisms of protection of these nucleotide precursors are known to be intracellular conversion of thymidine to thymidylate and of hypoxanthine to the purine nucleotide inosinic acid. As such, the observed protection profile suggests that LY231514 has both antipyrimidine and antipurine effects. Typically, the effects of TS inhibitors are fully reversed by thymidine alone, and those of GARFT inhibitors by hypoxanthine alone. On the other hand, DHFR inhibitors, which are known to affect both thymidylate and purine nucleotide biosynthesis, require the combination of thymidine and hypoxanthine for reversal of toxicity. However, unlike LY231514, DHFR inhibitors are not generally significantly protected by either agent alone.
Subsequent studies of LY231514 focused on drug uptake, cellular retention and possible intracellular targets (Shih et al, 1997) . Cellular entry of LY231514 via the reduced folate carrier was shown by examining drug cytotoxicity against mutant lines engineered to express different folate receptors and transport proteins. LY231514 was shown to be and excellent substrate for the enzyme folylpolyglutamate synthetase , suggesting the active intracellular agent to be polyglutamated forms of LY231514. Evaluation against a panel of purified folatedependent enzymes showed the inhibitory constants (K) of LY231514-glu5 for TS, DHFR and GARFT to be 1.3, 7.2 and 65 nM respectively. Taken together with the intracellular drug concentration, estimated to be greater than 10 ,uM (RM Schultz, unpublished observation), these data suggested that LY231514 could potentially be a multitargeted antifolate, and that combined inhibition of TS, DHFR and GARFT would explain the metabolite protection profile discussed above.
The studies described below were conducted with the intention of correlating the in vitro data obtained using purified enzymes with changes in cellular metabolite pools. Specifically, we have examined the effects of LY231514 on folate and nucleoside triphosphate pools in CCRF-CEM cells. At the same time, for the purposes of mechanistic comparison and analytical technique validation, parallel studies were conducted with the three folate analogues shown in Figure 2 , i.e. raltitrexed, methotrexate and LY309887, representing known inhibitors of TS, DHFR and GARFT, respectively, which are three potential targets of LY23 1514.
MATERIALS AND METHODS
Methylamine (40% aqueous solution) was purchased from Aldrich Chemical Co. Sodium periodate, all of the nucleotide triphosphates, methotrexate [(+)Amethopterin], folic acid, p-aminobenzoic acid and 5-formyl-[6R,S]-THF were obtained from Sigma. The 6(R,S)-diasteriomers of THF 5,10-methyleneTHF, 10-formylTHF and 5-methylTHF were purchased from Dr B Schircks Laboratories (Jona, Switzerland) . [3',5',7,9'-3H(N) . In this medium, cells were seeded at 2-5 x 105 ml-l and cultured for 16 h when cellular uptake of this vitamin, on a per cell basis, reached a maximum (data not shown). At this time, drugs were added and incubation was allowed to resume for the indicated duration. The extraction and analyses of folate pools were conducted according to the published methods (Wilson and Home, 1983) . At the time of harvest, the cells were spun down, washed twice in phosphate-buffered saline, counted, assessed for radioactivity and immediately frozen at -70°C in a pH 7.6 buffer containing 0.2 M HEPES, 2% each of ,B-mercaptoethanol and ascorbate. Subsequently, the samples were thawed, the cells were disrupted with three short bursts from a Bronson probe and brought to 900C for 2 min to inactivate the endogenous enzymes.
After removal of cell debris and denatured proteins by centrifugation for 10 min at 14 000 r.p.m. in an Eppendorf Model 5415 microcentrifuge, the supematant was combined with an aliquot of rat plasma equal to one-third of the volume of the extract and was incubated for 3 h to hydrolyse the polyglutamyl residues from the endogenous folate derivatives (Wilson and Home, 1983) . Independent experiments showed that in 3 h, the level of rat plasma used completely converted 16 nmol of pteroyltetra-y-L-glutamate to folic acid. Afterwards, the proteins in the extracts were heat denatured and removed by centrifugation as before. The supematant was analysed by ion-pair chromatography as previously described British Journal of Cancer (1998) (top) and radioactivity (bottom) in column effluent. Each sample included the mixture of unlabelled standard folate derivatives coinjected with extracts of CCRF-CEM cells containing tritium-labelled folyl metabolites prepared as described under Methods. The drug concentrations used were 1.0 pM methotrexate, 1.0 pM LY309887, 30 nM raltitrexed and 300 nM LY231514 and the drug exposure time was 4 h in all cases (Wilson and Home, 1983) . Accordingly, a Beckman IP column (4.6 x 25 cm) was first equilibrated in 5 mm tetrabutylammonium phosphate, pH 7.5, containing 17% ethanol. After sample injection, the column was developed initially isocratically using the equilibrating solvent for 40 min, then followed by linearly increasing the ethanol proportion from 17% to 40% between 40 and 47 min, and finally holding it at 40% for the remaining 17 min of the run. The gradient was generated on a Spectra-Physics SP8800 ternary highperformance liquid chromatography (HPLC) pump system, and the effluent was monitored sequentially by absorbance at 280 nm and by radioactivity using a Spectra Physics FOCUS optical scanning detector and a Radiomatic Radio-chromatography Detector Series A-100 connected in series. The delay between the two types of measurement was less than 15 s. The radioactive peaks of cellular folylmonoglutamates were identified by absorbance peaks of co-injected authentic standards. The chromatography gave adequate resolution of all of seven folate derivatives and p-aminobenzoate. By carrying these standard compounds individually through the entire protocol, the overall recovery of p-aminobenzoate, 10-formylTHF, THF, 5-formylTHF, 5-methylTHF and folic acid was assessed to be 80-85%; however, the recovery for DHF was only 43%, and all 5,10-methyleneTHF was hydrolysed to THF. Nucleotide analyses were performed as described in the literature (Garrett and Santi, 1979) . The CCRF-CEM cells were seeded in fresh complete medium at 3 x 105 ml-' and cultured for 12-16 h before treatment. After exposure to drugs, the cells were harvested, washed twice in phosphate-buffered saline and extracted three times with 3:2 ethanol-water mixture. The extracts were combined, lyophilized and redissolved in 20 mm phosphate, pH 7. Ribonucleoside triphosphates were analysed directly by HPLC using a Whatman Partisil 10 SAX column (4.6 x 250 mm), eluted isocratically with a solvent system comprising ten parts 0.4 M ammonium phosphate, pH 4.45, and one part acetonitrile. Analysis of deoxyribonucleoside triphosphates required prior destruction of the corresponding ribonucleoside triphosphates. This was accomplished by making the extract to the final concentration in 20 mm sodium periodate and 0.2 M methylamine. The treated extract was analysed by HPLC using the SAX column, British Journal of Cancer (1998) eluted isocratically with a solvent system comprising ten parts 0.4 M ammonium phosphate, pH 3.25, and one part acetonitrile. These HPLC analyses were performed on a Beckman System Gold unit, connected to a Scanning Detection Module 167 for monitoring the effluent spectrophotometrically at 254 nm. The output signal was fed through a PE Nelson 900 analogue to digital converter into a Hewlett-Packard HP1000 mainframe computer for calculations. The nucleotide data at each time point are normalized to the zero-time value of a particular culture. Recovery of individual nucleotides was not assessed. However, the zero-time values we determined for UTP, 1.28 ± 0.12; CTP, 0.53 ± 0.05; ATP, 3.64 ± 0.24; GTP, 0.82 ± 0.05; dTTP, 0.046 ± 0.003; dCTP, 0.007 ± 0.001; dATP, 0.05 ± 0.002 and dGTP, 0.023 ± 0.001 nmol/million cells (n = 12, mean ± std error) are in the same range as those reported by others for this cell line (Kinahan et al, 1979; Pizzorno et al, 1991) . 
RESULTS
Representative HPLC profiles of folate pools extracted from CCRF-CEM cells are shown in Figure 3 . Although the HPLC method used is capable of resolving all the naturally occurring folylmonoglutamate derivatives, 5,10-methyleneTHF could not be detected directly because of its instability under the extraction condition. 5,10-MethyleneTHF was degraded to THF, and thus the two folates were determined together. The major folyl species of CCRF-CEM cells in log phase not exposed to drug consisted of 10-formylTHF, THF (which represented THF + 5, 10-methyleneTHF), a small amount of DHF and 5-methylTHF (Figure 3 ). The intracellular folate content was estimated to be 7.4 ± 0.8 glM (n = 5, mean ± standard error), which is in good agreement with values reported for other cell lines in the literature (Strong et al, 1990) . Exposing the cells to 0.1 JIM methotrexate (24 times the IC50 in CCRF-CEM cells) caused the loss of 10-formylTHF, THF and 5-methylTHF with the concomitant appearance of DHF and a new peak eluting just after DHF, which was assumed to be 10-formylDHF (Figure 3 ). Increasing the concentration to 1 gM methotrexate resulted in only a slightly larger effect.
Taking the recovery into consideration, the loss of 10-formylTHF, THF and 5-methylTHF accounted for about 85% of the accumulation of DHF + 10-formylDHF (Figure 4 ).
The folate pools responded to LY309887 at 0.1 and 1.0 gM (34 and 340 times the IC50) similarly by an accumulation of 10-formylTHF. This could be accounted for by the loss of THF (THF + 5,10-methyleneTHF, Figure 5 ), a result that is consistent with LY309887 having created a blockage at GARFT.
Neither raltitrexed at 30 nM (20 times the IC50) nor LY23 1514 at 300 nm (12 times the IC50) caused a very large change in the folate pool in 8 h (Figures 3 and 6 ). In particular, there was no accumulation of DHF. A tenfold increase in the drug concentrations did not result in a significantly larger effect (data not shown). The data of LY231514 and raltitrexed in Figure 6 were compared by an analysis of variance (ANOVA) with the experiments run on different days treated as blocks. While there were not enough data to make a distinction between the effects of the two drugs at the 8-h time points, the 4-h time points showed that the changes induced by raltitrexed and LY231514 were +3.5% and -1.3%, respectively (P = 0.011), in THF (THF +5,10-methyleneTHF) and were -6.4% and +0.3% (P = 0.003), respectively, in 10-formylTHF.
The time-dependent changes in ribonucleoside and deoxyribonucleoside triphosphate pools as a result of exposing CCRF-CEM cells to folate-based drugs at doses about one log above IC 5 are Drug exposure time (h) Our data for the effects of methotrexate and LY309887 on cellular folate pools were fully consistent with the known mechanism of action of these drugs. Accumulation of DHF and 10-formylDHF in cells exposed to methotrexate is a well documented consequence of DHFR inhibition (Allegra et al, 1986; Ackland and Schilsky, 1987; Baram et al, 1987; Morrison and Allegra, 1989; Matherly and Muench, 1990; Trent et al, 1991) . In our analysis, we were able to quantitatively account for the build-up in DHF species from the combined depletion in 10-formylTHF, THF and 5-methylTHF. However, we observed a complete disappearance of 10-formylTHF, while others have previously reported only a partial loss. This difference might have resulted from a combination of the use of different folates as the source of the radiolabel, as well as the total folate concentration in the cell culture medium.
With 100 nM 5-formylTHF as the source of label and folate, it would not be unreasonable to expect only a small amount of 5-methylTHF. The trace amount of folic acid present was probably due to spurious oxidation during extraction, as there is no known cellular mechanism for conversion of 5-formylTHF to folic acid.
Thus, during inhibition of DHFR, a depletion in the functional folate pool involved the loss of 10-formylTHF. Other investigators have reported labelling with 2.3 gM folic acid, which would result in higher 5-methylTHF and folic acid levels (Allegra et al, 1986; Baram et al, 1987; Matherly and Muench, 1990; Trent et al, 1991) . These were expected to be the first folyl species to be lost, when DHFR was inhibited. However, in their instance, depletion of folate stopped as a result of inhibition of TS by the accumulation of 10-formylDHF, before significant loss of 10-formylTHF.
The accumulation of 10-formylTHF observed with LY309887
( Figure 5 ) is consistent with inhibition at GARFT (Habeck et al, 1994) . On the other hand, the anticipated consequence of TS inhibition is an accumulation of 5,10-methyleneTHF, which, unfortunately, is a folate species that could not be differentiated from THF in our assay. Therefore, if raltitrexed had caused such an increase in 5,10-methyleneTHF at the expense of THF, it would not have been detected. Thus, the lack of a substantial effect of raltitrexed on the folate pool was not an unexpected result. Nevertheless, exposure to raltitrexed did trigger a very slight rise in the level of THF and a compensatory fall in that of 10-formylTHF ( Figure 6 ).
An equally small effect on the folate pool was observed with LY231514, with a trend for THF and 10-formylTHF consistently opposite to that for raltitrexed. Based on an analogy to the observed accumulation of 10-formylTHF by LY309887 ( Figure  5 ), the differential effects on 10-formylTHF and THF induced by LY231514 and raltitrexed ( Figure 6 ) might be attributable to a difference in their effects on GARFT. This hypothesis, however, would have to be confirmed by direct measurement of metabolic flux through the de novo purine nucleotide biosynthetic pathway.
The major message from the folate analysis was the lack of DHF accumulation induced by either raltitrexed or LY231514 in CCRF-CEM cells under very similar conditions in which DHF was detected with methotrexate. When TS was strongly inhibited, there would be little or no conversion of 5,10-methyleneTHF to DHF, and DHFR would be effectively inactive. Thus, the lack of intracellular accumulation of DHF by LY231514 does not contradict the fact that this drug inhibits purified DHFR in vitro. However, it does suggest the primary target of LY23 1514 to be TS in CCRF-CEM cells. In the presence of significant TS inhibition, it is difficult to study the metabolic effect of a drug on DHFR. Concurrent inhibition of two sequential steps in the same metabolic pathway can be redundant with respect to the end product.
The intracellular level of each nucleotide is a balance of synthesis, use and salvage (Kornberg, 1980; Reichard, 1988) . The biosynthetic pathways of individual nucleotides are interconnected in that they share several common intermediates, and that the end product of one pathway serves as an allosteric regulator of the enzymes in the others. Moreover, the ribonucleotides are the precursors for RNA, as well as for their respective deoxyribose counterparts, and the syntheses of deoxyribonucleotides and DNA are under cell cycle regulation.
Against this background is the well known fact that methotrexate exhibits inhibitory activities against the biosynthesis of both pyrimidine and purine nucleotides (Ackland and Schilsky, 1987) . Thus, the depletion of both ATP and GTP caused by methotrexate observed here and by others (Kinahan et al, 1979; Taylor et al, 1982a and b) is consistent with the antipurine effect of methotrexate. Furthermore, similar depletion of ATP and GTP was observed with the GARFT inhibitor LY309887 and was reported for lometrexol (Pizzorno et al, 1991; Chong and Tattersall, 1995) , as well as for other antipurine compounds, such as 6-methylmercaptopurine ribonucleoside (Cohen and Sadee, 1983) . Our data for methotrexate and LY309887 implied that, if there was an antipurine effect, it should have been evident in the ribonucleotide pools. Thus, it was not surprising that raltitrexed, having no known antipurine effect, did not show any significant effects on ribonucleoside triphosphate levels. Similar results were obtained with LY231514, despite previous reports on its inhibition on purified GARFT (Kj = 65 nm for LY231514-glu5) (Shih et al, 1997) in vitro. In the presence of possible salvage and other compensatory pathways, the magnitude of the anti-GARFT effect of LY231514 might be insufficient to cause significant British Journal of Cancer (1998) 78(Supplement 3), [27] [28] [29] [30] [31] [32] [33] [34] impact on the intracellular ribonucleoside triphosphate pools in CCRF-CEM cells.
Depletion of intracellular dTTP is the most notable consequence of a retardation of the thymidylate cycle, involving inhibition of either TS or DHFR (Kinahan et al, 1979; Jackson, 1992; Aherne et al, 1996; Kunz, 1996; Weber et al, 1996) . The fall of dTTP observed with methotrexate, raltitrexed and LY231514 was very rapid. On the other hand, although LY309887 also depleted dTTP, it did so much more gradually.
It is well known that when cells are nutritionally deprived of thymine, the intracellular level of dTTP falls together with simultaneous perturbations in the other three deoxyribonucleoside triphosphates (Kunz, 1996) . For example, studies with 5-fluorodeoxycytidine and CB37 17 have shown a rise in dATP level and a fall in dGTP level accompanying dTTP depletion (Newman and Santi, 1982; Jackson et al, 1983; Kwok and Tattersall, 1992) . With raltitrexed and LY231514, we observed an accumulation of dATP together with the disappearance of both dCTP and dGTP, concomitant with dTTP depletion. The changes in dCTP and dGTP may be rationalised by what is known about dCMP deaminase and ribonucleoside diphosphate reductase, the two enzymes that control the biosynthesis of deoxyribonucleotide (Kinahan et al, 1979; Kornberg, 1980; Oliva et al, 1996) . It is known that dCMP deaminase is inhibitable by dTTP. Possibly, the fall of dTTP as a result of TS inhibition could restore dCMP deaminase activity, causing dCMP to be converted to dUMP. This could in turn lead to dCTP depletion via the rapid intracellular equilibrium between the mono-, di-and triphosphate forms of the nucleoside. At the same time, ribonucleoside diphosphate reductase, which converts GDP to dGDP, is allosterically enhanced by dTTP and inhibited by dATP (Reichard, 1988) . Thus, the fall of dGTP observed with reltitrexed and LY231514 here may be consistent with the retardation in the synthesis of dGDP under conditions of low dTTP and high dATP.
The mechanism for the changes in dATP levels is not well understood. However, it is interesting to note that for methotrexate, a drug with both antipyrimidine and antipurine effects, depletion of dTTP occurred without a concommitant increase in dATP. Furthermore, Chong and Tattersoll (1995) reported that the combination of a GARFT inhibitor and a TS inhibitor prevented the rise in the dATP pool seen with the TS inhibitor alone. Based on these observations, the difference in the rate of dATP accumulation induced by raltitrexed and LY231514 would be attributable to the difference in antipurine effect of the two drugs, a hypothesis that can be verified by direct evaluation of the metabolic flux from glycine to inosinic acid.
In conclusion, our study showed that the new folate analogue LY23 1514 was an antimetabolite distinct from methotrexate, LY309887 and raltitrexed. The data presented above are consistent with LY231514 in affecting the thymidylate cycle as well as possibly de novo purine nucleotide biosynthesis in CCRF-CEM cells. Although, in the present study with CCRF-CEM cells, a significant perturbation of the ribonucleotide pools was not observed with LY231514, comparing the changes in dATP induced with other folate-based drugs provided evidence suggestive of the possible presence of an effect on purine nucleotides. The inhibition of the thymidylate cycle contributed by strong inhibition of TS could mask the effect of LY231514 on DHFR, as a result of the two enzymes being sequential steps in the same metabolic pathway. As such, it will be interesting to study a cell line with overexpressed TS levels in future. Evaluation in other cell lines is in progress to confirm the generality of the observations reported in this paper. The phase I evaluation of LY231514 has been completed (Rinaldi et al, 1995 (Rinaldi et al, , 1996 McDonald et al, 1996) . A broad phase II clinical study using the q2 1 days at 500-600 mg m-2 is currently in progress and preliminary results indicate early favourable responses in several tumour types (Clarke et al, 1997; Cripps et al, 1997; John et al, 1997; Miller et al, 1997; Rusthoven et al, 1997; Smith et al, 1997 ). It will be very interesting to see how the mechanistic subtleties between the folate-based drugs discussed in this paper eventually translate into differences in clinical efficacy and toxicity.
